Pedra Technology Pte Ltd

Pedra Technology Pte Ltd develops innovative perfusion monitoring solutions that enhance treatment protocols for patients suffering from Peripheral Arterial Disease and Critical Limb Threatening Ischemia, improving clinical decision-making in vascular procedures. Founded in 2014 and headquartered in Singapore, Pedra Technology Pte Ltd focuses on advanced medical technologies. The firm has completed 2 deals, with its most recent funding round being a Series B in August 2020, raising USD 2. 58 mn from investors including Koninklijke Philips N.

V. , M&L Healthcare, and SEEDS Capital. The CEO, Kareen Looi, leads the company as it continues to develop its offerings in the healthcare sector. Pedra Technology specializes in advanced perfusion monitoring solutions aimed at treating patients with Peripheral Arterial Disease (PAD) and Critical Limb Threatening Ischemia (CLTI).

Their core product, the PEDRA Xauron Perfusion System, is a groundbreaking device that provides real-time, quantitative monitoring of deep-tissue perfusion levels. This system employs advanced laser technology to deliver immediate feedback on foot tissue perfusion, enabling physicians to make informed decisions during angioplasty procedures. The device is designed for use in hospital angio suites and is compatible with existing angiographic imaging systems, primarily servicing healthcare providers, hospitals, and surgical centers specializing in vascular surgery across the United States, Europe, and Asia. Pedra Technology generates revenue through the sale and deployment of its PEDRA Xauron Perfusion System to healthcare institutions.

The business operates on a direct-to-business model where hospitals and surgical centers purchase the device as part of their medical equipment inventory. Transactions typically involve one-time purchases, with opportunities for ongoing service agreements regarding maintenance and support. Additionally, the company may provide training and integration into existing medical practices, fostering long-term partnerships with clients. In 2023, the company reported an EBITDA of USD -124,360.

Pedra Technology aims to expand its product line with the launch of new monitoring devices aimed at innovative treatments for vascular conditions, targeting the completion of these new products by late 2023. The company also plans to enter new geographical markets in North America and Europe, with an anticipated expansion by mid-2024. The funds raised in the Series B round will be utilized to support research and development, as well as to facilitate market entry strategies and enhance the sales network within these regions.